Mavacamten

(Camzyos®)

Camzyos®

Drug updated on 4/18/2024

Dosage FormCapsule (oral; 2.5 mg, 5 mg, 10 mg, 15 mg)
Drug ClassCardiac myosin inhibitors
Ongoing and
Completed Studies
ClinicalTrials.gov

Indication

  • Indicated for the treatment of adults with symptomatic New York Heart Association (NYHA) class II-III obstructive hypertrophic cardiomyopathy (HCM) to improve functional capacity and symptoms.

Latest News

loading GIF

Summary
This AI-generated content is provided without warranty, with no liability accepted for reliance on it. Learn more.

  • Mavacamten (Camzyos) is indicated for the treatment of adults with symptomatic New York Heart Association (NYHA) class II-III obstructive hypertrophic cardiomyopathy (HCM), improving functional capacity and symptoms.
  • Five studies were reviewed, all consistently reporting that mavacamten significantly improved at least one NYHA functional class in patients with HCM, indicating its efficacy.
  • Mavacamten also showed a significant reduction in Septal Reduction Therapy rates across studies, suggesting its potential to decrease the need for further invasive therapy.
  • Safety data revealed a slight increase in adverse events with mavacamten use; however, these were not statistically significant for severe adverse events when compared to placebo. Common side effects included atrial fibrillation and decreased left ventricular ejection fraction.
  • Studies included patients of Caucasian and Chinese ethnicity, primarily aged 56 to 57.9 years old. While effective in obstructive HCM cases, more research is suggested on non-obstructive HCM patient benefits.
  • Compared mainly against placebos rather than other specific treatments for HCM within the studies reviewed; mavacamten presents itself as a disease-specific option due to its mechanism as a cardiac myosin inhibitor targeting the underlying pathology of HCM - offering an innovative approach towards managing this condition.